Vedolizumab is approved by the FDA for the treatment of moderate to severe Crohn disease or ulcerative colitis, both forms of inflammatory bowel disease (IBD), who have had an inadequate response or loss of response to immunomodulators, tumor necrosis factor inhibitors, or corticosteroid therapy.
Vedolizumab is approved by the FDA for the treatment of moderate to severe Crohn disease (CD) or ulcerative colitis (UC), both forms of inflammatory bowel disease (IBD), who have had an inadequate response or loss of response to immunomodulators, tumor necrosis factor (TNF) inhibitors, or corticosteroid therapy.
A recent study sought to assess the budgetary impact of including vedolizumab in a health plan formulary as a preferred first-line biologic therapy for the treatment of UC and CD rather than only for patients who have previously failed on anti-TNF therapy.
Researchers developed a budget impact model to examine the incremental impact on a health plan’s budget if vedolizumab were to be included among existing preferred first-line biologic treatments. In an effort to reflect current treatment paradigms, researchers modeled the most current treatment options available in potential health plans, including newly approved therapies and biosimilars. “Incorporating a biosimilar in our budget impact analysis of including vedolizumab as a first-line biologic treatment represents a conservative approach, because the use of any biosimilar may result in lower costs for the payer,” wrote the authors.
In order to account for differences among health pans, the study authors considered 3 hypothetical formulary cases before the introduction of vedolizumab:
In total, researchers found that adding vedolizumab as a first-line treatment in Case 1’s hypothetical formulary demonstrated the most cost-savings, which increased from $1.63 million in the first year of the experiment to $4.68 million in the third year. For Case 2, the total annual cost savings increased from $587,000 in the first year to $1.69 million in the third year; and from $134,000 to $378,000 in Case 3. Additionally, real-world dose escalation patterns contributed to the observed differences in cost savings across the plans. In Case 1, the introduction of vedolizumab as a preferred first-line treatment substantially saves on treatment costs because it reduces the use of adalimumab more in Case 1 than in the other cases.
“The inclusion of vedolizumab on parity with existing preferred first-line biologic treatments is expected to have a substantial cost-savings impact to a health plan,” wrote the authors. “The cost-savings in this study were most pronounced in Case 1, when vedolizumab was introduced as a parity-preferred treatment alongside adalimumab as first-line treatment and alongside infliximab as second-line treatment.”
Reference
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as another first-line biologic option for ulcerative colitis and Crohn’s disease. Am Health Drug Benefits. 2018;11(5):253-262. PMCID: PMC6207303.
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Comparable Pregnancy and Infant Milestones With Infliximab Biosimilars vs Originator in IBD
March 15th 2025A study evaluating pregnancy outcomes and infant developmental milestones found similar outcomes between pregnant women with inflammatory bowel disease (IBD) who received reference infliximab and those who received a biosimilar.